Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Immunopathogenesis of Multiple Sclerosis: Molecular and Cellular Mechanisms and New Immunotherapeutic Approaches Publisher Pubmed



Aliyu M1, 2 ; Zohora FT3 ; Ceylan A4 ; Hossain F3 ; Yazdani R5 ; Azizi G5, 6
Authors

Source: Immunopharmacology and Immunotoxicology Published:2024


Abstract

Background: Multiple sclerosis (MS) is a central nervous system (CNS) demyelinating autoimmune disease with increasing global prevalence. It predominantly affects females, especially those of European descent. The interplay between environmental factors and genetic predisposition plays a crucial role in MS etiopathogenesis. Methods: We search recent relevant literature on reputable databases, which include, PubMed, Embase, Web of Science, Scopus, ScienceGirect using the following keywords: multiple sclerosis, pathogenesis, autoimmunity, demyelination, therapy, immunotherapy. Results: Various animal models have been utilized to study MS etiopathogenesis and therapeutics. Autoreative T cells within the CNS recruit myeloid cells through chemokine expression, leading to the secretion of inflammatory cytokines driving the MS pathogenesis, resulting in demyelination, gliosis, and axonal loss. Key players include T cell lymphocytes (CD4+ and CD8+), microbiota B cells, and neutrophils. Signaling dysregulation in inflammation pathways and the immunogenetic basis of MS are essential considerations. The pathogenesis of MS involves demyelination, gliosis, and axonal loss driven by inflammatory cytokines. While T cells are traditionally recognized as central to MS, evidence suggests a significant role for B cells and neutrophils. High neutrophil-to-lymphocyte ratios correlate with MS severity, indicating their contribution to disease progression. Dysregulated signaling pathways further exacerbate MS progression. Conclusion: MS remains incurable, but disease-modifying therapies, monoclonal antibodies, and immunomodulatory drugs offer hope for patients. Ongoing research into the immunogenetics and immunoregulatory roles of gut microbiota continues to shed light on potential therapeutic avenues. Understanding the complex interplay between genetic predisposition, environmental factors, and immune dysregulation is critical for developing effective treatments for MS. © 2024 Informa UK Limited, trading as Taylor & Francis Group.
Other Related Docs
7. Monoclonal Antibodies in Multiple Sclerosis Treatment, Translational Neuroimmunology: Multiple Sclerosis: Volume 8 (2023)
8. Immune-Mediated Cognition Impairment in Multiple Sclerosis, Translational Neuroimmunology: Multiple Sclerosis: Volume 8 (2023)
14. B Cells in Multiple Sclerosis Therapy—A Comprehensive Review, Acta Neurologica Scandinavica (2018)
18. Introduction to the Neuroimmunology of Multiple Sclerosis, Translational Neuroimmunology: Multiple Sclerosis: Volume 8 (2023)